Social distancing and stay-at-home measures provided scientists with a natural experiment to study social phenomena that hinge precisely on human mobility and contact — including criminal activity. A study by Center for the U.S. and Mexico experts and co-authors explores the relationship between COVID-19 and criminal activity in Mexico.
Sean Fiorella, Tony Payan, Daniel Potter, Rodrigo Montes de OcaJuly 23, 2023
Observations that peritoneal dialysis (PD) may be an effective, lower-cost alternative to hemodialysis for the treatment of ESKD have led to policies encouraging PD and subsequent increases in its use in the United States.
Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).
The intense marketing of unproven stem cell interventions has become an international health concern. The authors offer resources and suggestions for physicians seeking to effectively counsel patients and respond to their questions about various stem cell therapies.
This study finds that Maryland's all-payer model for healthcare comparatively lowered the risk of complications from surgery, as well as reducing increases in associated costs.
Anaeze C. Offodile II, Oluseyi Aliu, Andrew W. P. Lee, Jonathan E. Efron, Robert S. D. Higgins, Charles ButlerSeptember 28, 2021
The unproven stem cell intervention industry is a worldwide, direct-to-consumer market where clinics offer stem cells or stem cell-derived components to patients with little to no scientific or clinical basis. In this paper, the authors call for the establishment of a World Health Organization Expert Advisory Committee on Regenerative Medicine to tackle this issue and provide guidance. Stem Cell Reports: https://doi.org/10.1016/j.stemcr.2021.05.004
The authors sought to develop and test a tool that accurately predicts the unique financial burden to individual patients undergoing treatment for breast cancer. JCO Clinical Cancer Informatics, an American Society of Clinical Oncology Journal
Anaeze C. Offodile II, Chris Sidey-Gibbons, André Pfob, Malke Assad, Stefanos Boukovalas, Yu-Li Lin, Jesse Creed Selber, Charles ButlerMarch 26, 2021
